Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

244
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
244
Subviral Agents01:29

Subviral Agents

525
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
525
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.3K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K
Pharmacovigilance01:19

Pharmacovigilance

1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

227
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
227
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.2K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tradipitant: First Approval.

Drugs·2026
Same author

Depemokimab: First Approval.

Drugs·2026
Same author

Sibeprenlimab: First Approval.

Drugs·2026
Same author

Zongertinib: First Approval.

Drugs·2026
Same author

Rilzabrutinib: First Approval.

Drugs·2025
Same author

Dorocubicel: First Approval.

Molecular diagnosis & therapy·2025

相关实验视频

Updated: Jan 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.2K

昂拉迪维尔:首次获得批准

Arnold Lee1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|September 25, 2025
PubMed
概括
此摘要是机器生成的。

昂拉迪维尔是一种新的抗病毒药物,可以有效地抑制流感A病毒的复制. 它已在中国首次获得批准,用于治疗成年人无并发性流感A.

更多相关视频

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.3K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.8K

相关实验视频

Last Updated: Jan 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.2K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.3K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.8K

科学领域:

  • 病毒学 病毒学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 流感A型病毒对公众健康构成重大威胁.
  • 新型抗病毒药物的开发对于控制流感至关重要.
  • 小分子抑制剂提供有针对性的治疗策略.

研究的目的:

  • 总结一下新型RNA聚合酶抑制剂onradivir的发展情况.
  • 为了突出导致其首次监管批准的里程碑.
  • 详细说明其在治疗无并发性流感A的疗效.

主要方法:

  • 昂拉迪维尔向了A型流感病毒RNA聚合酶的PB2封锁结合域.
  • 第三阶段临床试验 (NCT04683406) 的数据支持了批准.
  • 由广东瑞诺生物科技公司开发.

主要成果:

  • 昂拉迪维尔证明了对流感A病毒复制的强有力的抑制.
  • 该药物于2025年5月在中国首次获得批准.
  • 在成年人治疗无并发性A型流感时确立了疗效.

结论:

  • 昂拉迪维尔代表了A型流感治疗的重大进展.
  • 药物的作用机制为病毒抑制提供了有针对性的方法.
  • 监管部门的批准标志着这一疗法可供使用的关键里程碑.